Benjamin Ellezam

Centre Hospitalier Universitaire Sainte-Justine — Canada

Medicine · Health Sciences

32h-index5.4kcitations162works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(68), Neuroblastoma Research and Treatments(60), Neurofibromatosis and Schwannoma Cases(16), Inflammatory Myopathies and Dermatomyositis(16), Chromatin Remodeling and Cancer(13)

Publications158 total

Spatial transcriptomics reveals mechanism of autoimmunity driven by internalized autoantibodies
2026Open Access
Revisiting the link between oropharyngeal dysphagia and cancer in autoimmune myositis: a descriptive study
Arthritis Research & Therapy·2025Open Access
PTHP-09. High-resolution proteomic analysis of medulloblastoma clinical samples identifies MYC immunohistochemistry as a powerful outcome predictor outperforming genetic amplification detection
Neuro-Oncology·2025
Preterm Birth Conditions Alter Muscle Stem Cells and Their Niche, Causing Lasting Impairments in Muscle Regeneration and Function
Journal of Cachexia Sarcopenia and Muscle·2025Open Access
Aberrant EZHIP expression drives tumorigenesis in osteosarcoma
Nature Communications·2025· 3 citedOpen Access
Expanding the Clinical Spectrum of Myositis with Prominent B-Cell Aggregates (BCM)
The Journal of Rheumatology·2025Open Access
Clinical pearls and histopathological features help discriminate toxic rhabdomyolysis from immune-mediated necrotizing myopathy in statin-exposed patients
Neuromuscular Disorders·2025· 1 cited
Rapid clinical and transcriptomic response to anifrolumab in refractory anti-TIF1γ–positive juvenile dermatomyositis
Annals of the Rheumatic Diseases·2025· 5 cited
High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy-resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor
Neuro-Oncology·2025· 1 citedOpen Access
Supplementary Table S4 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025Open Access
Supplementary Table S3 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025Open Access
Supplementary Figure S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025Open Access
Data from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025Open Access
Supplementary Figure S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025Open Access
Supplementary Data S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025Open Access
Supplementary Table S5 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025Open Access
Supplementary Table S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025Open Access
Supplementary Table S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025Open Access
Supplementary Figure 3 from FOXR2 Targets LHX6<sup>+</sup>/DLX<sup>+</sup> Neural Lineages to Drive Central Nervous System Neuroblastoma
2025Open Access
Supplementary Figure 4 from FOXR2 Targets LHX6<sup>+</sup>/DLX<sup>+</sup> Neural Lineages to Drive Central Nervous System Neuroblastoma
2025Open Access
page 1 of 8Next →

Frequent Co-authors

Nada Jabado(21), Damien Faury(12), Alexander G. Weil(12), Claudia L. Kleinman(10), Jason Karamchandani(9), Sébastien Perreault(8), Nicolas Jay(6), Keith L. Ligon(6), Brian Krug(6), Carol Chen(6), Leonie G. Mikael(6), Stephen C. Mack(6), Océane Landon‐Cardinal(6), Lisa McKerracher(5), Jacek Majewski(5), Ashot S. Harutyunyan(5), Michele Zeinieh(5), Benjamin A. García(5), Selin Jessa(5), Steven Hébert(5)